Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis
Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH
Aging (Milan, Italy) · 131 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1998-10-01 · Aging (Milano) · vol. 10 · número 5 · págs. 385–394
- Editorial
- Springer Science+Business Media
- Citado
- 188 citas · más que el 85% de estudios similares · 1.9× el promedio de su campo
- Referencias
- 44 trabajos
- Acceso
- De pago
- Áreas de investigación
- Bone health and osteoporosis research · Fatty Acid Research and Health · Bone Metabolism and Diseases
- Palabras clave
- gamma-linolenic acid, eicosapentaenoic acid, calcium supplementation, senile osteoporosis, bone mineral density, bone turnover markers, osteocalcin, deoxypyridinoline, alkaline phosphatase, older women, omega-3 fatty acids, lumbar spine, femoral bone density
- MeSH
- femur, lumbar vertebrae, humans, osteoporosis, postmenopausal, calcium, alkaline phosphatase, eicosapentaenoic acid, gamma-linolenic acid, amino acids, osteocalcin, drug therapy, combination, pilot projects, bone density, aged, aged, 80 and over, female, male
5 autores
- Marlena C. Kruger🇿🇦University of Pretoria
- H. Coetzer🇿🇦University of Pretoria
- R. de Winter🇿🇦University of Pretoria
- George Sebastian Gericke🇿🇦University of Pretoria
- D.H. van Papendorp🇿🇦University of Pretoria
Resumen
El texto original del estudio, en el idioma en que se publicó.
Recent animal work suggests that gamma-linolenic acid (GLA) and eicosapentaenoic acid (EPA) enhance calcium absorption, reduce excretion and increase calcium deposition in bone. A pilot study was set up to test the interactions between calcium and GLA + EPA in humans. Sixty-five women (mean age 79.5), taking a background diet low in calcium, were randomly assigned to GLA + EPA or coconut oil placebo capsules; in addition, all received 600 mg/day calcium as the carbonate. Markers of bone formation/degradation and bone mineral density (BMD) were measured at baseline, 6, 12 and 18 months. Twenty-one patients were continued on treatment for a second period of 18 months, after which BMD (36 months) was measured. At 18 months, osteocalcin and deoxypyridinoline levels fell significantly in both groups, indicating a decrease in bone turnover, whereas bone specific alkaline phosphatase rose indicating beneficial effects of calcium given to all the patients. Lumbar and femoral BMD, in contrast, showed different effects in the two groups. Over the first 18 months, lumbar spine density remained the same in the treatment group, but decreased 3.2% in the placebo group. Femoral bone density increased 1.3% in the treatment group, but decreased 2.1% in the placebo group. During the second period of 18 months with all patients now on active treatment, lumbar spine density increased 3.1% in patients who remained on active treatment, and 2.3% in patients who switched from placebo to active treatment; femoral BMD in the latter group showed an increase of 4.7%. This pilot controlled study suggests that GLA and EPA have beneficial effects on bone in this group of elderly patients, and that they are safe to administer for prolonged periods of time.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.